During the Trading Day
| 4.43 |  +0.01 / +0.23% |
Data as of 4:00pm ET | Day’s Change | |
| 4.44 | +0.01 / +0.23% |
| Volume: 200.00 |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $139.5M |
Company Description
Alimera Sciences, Inc. is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. The ILUVIEN product is an antidote for the treatment of diabetic macular edema, a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Alimera Sciences was founded on June 4, 2003 by C. Daniel Myers and David R. Holland and is headquartered in Alpharetta, GA.
Employees
Shareholders
| Mutual fund holders | 8.47% |
| Individual stakeholders | 37.05% |
| Other institutional | 20.39% |
Top Executives
| Charles Daniel Myers | President, Chief Executive Officer & Director |
| Richard S. Eiswirth, Jr., CPA | Secretary, Chief Operating & Financial Officer |
| Susan H. Caballa | Senior Vice President-Regulatory & Medical Affairs |
| Kenneth Green, PhD | Chief Scientific Officer & Senior Vice President |
| Philip Ashman, PhD | Senior Vice President & Managing Director-Europe |
.
